Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

SPBN: a free radical scavenger with potential in pediatric head trauma

Nov. 12, 1998

Pharmacological profile of the novel, selective kappa-opioid agonist HZ2

Nov. 12, 1998

Preparation and use of new CNS-active series reported by Pharmacia & Upjohn

Nov. 12, 1998

Improved dosage form of selegiline now on the U.K. market

Nov. 11, 1998

Neuroprotective effects of NCC-161, a new neuronal calcium antagonist

Nov. 11, 1998

Synthelabo presents new 5-HT1A inverse agonist with antagonist and anxiolytic-like activity in vivo

Nov. 11, 1998

PD-161989: novel AMPA/GLYN receptor antagonist related to PNQX

Nov. 11, 1998

Chugai describes inhibitors of iNOS, nNOS

Nov. 11, 1998

Synthelabo presents in vitro, ex vivo and in vivo data on new MAO-B inhibitor

Nov. 11, 1998

LY-300164 protects against kainate-induced neurotoxicity in vitro in a stereoselective manner

Nov. 11, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...